Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Filings indexed 205 across all filing types
Latest filing 2025-12-29 Director's Dealing
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-12-29 English
Director's Dealing 2025
Director's Dealing
2025-12-29 English
8-K
Regulatory Filings
2025-12-23 English
4
Director's Dealing
2025-12-19 English
8-K
Regulatory Filings
2025-12-17 English
Director's Dealing 2025
Director's Dealing
2025-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.